LDDN-0003499

LDDN-0003499 is a Src family tyrosine kinase inhibitor and anti-inflammatory agent. LDDN-0003499 reduces basal and Aβ-stimulated levels of active, phosphorylated Lyn and Src kinases, and attenuates Aβ-stimulated secretion of pro-inflammatory cytokines TNFα and IL-6 in microglial cells. LDDN-0003499 can be used for the research of Alzheimer's disease^[1]. In Vitro:LDDN-0003499 (0.5 nM-50 μM; 24 h) shows no toxicity to mouse microglial BV2 cells^[1].
LDDN-0003499 (0.5 nM-50 μM; 1 h) reduces the total protein phosphotyrosine level in murine microglial BV2 cells in a dose-dependent manner^[1].
LDDN-0003499 (0.5 nM-50 μM; 1 h) dose-dependently inhibits the basal activity levels of phosphorylated Lyn and Src in mouse microglial BV2 cells^[1].
LDDN-0003499 (0.5 nM-50 μM; 65 min) dose-dependently inhibits the Aβ-induced increase in the levels of activated phosphorylated Lyn and Src in mouse microglial BV2 cells^[1].
LDDN-0003499 (0.5 nM-50 μM; 1 h) reduces Aβ-stimulated secretion of TNF-α and IL-6 in mouse microglial BV2 cells in a dose-dependent manner^[1].
LDDN-0003499 (1 μM) exhibits moderately high NADPH-dependent clearance and low non-NADPH-dependent clearance in human and mouse liver microsomes^[1].